DeepHealth (formerly Kheiron Medical Technologies)

by DeepHealth (formerly Kheiron Medical Technologies)  · Based in United States →Empowering breakthroughs in care through imaging.
Oncology Radiology Women's Health

Regulatory Status Disclosed

Overview

DeepHealth, formerly Kheiron Medical Technologies, is an AI-powered health informatics company that develops solutions for diagnostic imaging. It is a wholly-owned subsidiary of RadNet, Inc.

DeepHealth’s portfolio includes AI-powered solutions across several specialties, including breast, prostate, chest, neuro, and thyroid health. These solutions are designed for radiologists and other healthcare professionals in various care settings, particularly those involved in large-scale diagnostic and screening programs.

The company’s offerings, such as the SmartMammo™ Breast Suite, integrate into existing diagnostic workflows, aiming to enhance diagnostic accuracy and workflow efficiency. For example, the Breast Suite includes AI-powered cancer detection, automated density assessment, and risk assessment, with capabilities to incorporate prior exams for comparison. DeepHealth also offers enterprise imaging solutions like the Diagnostic Suite™, which provides PACS functionality and advanced image management, and the Operations Suite™, which includes RIS functionality and real-time workflow management.

Notable capabilities include AI-assisted nodule detection in chest CT scans and the identification of breast arterial calcifications (BACs) on mammograms. DeepHealth’s cloud-native operating system, DeepHealth OS, aims to unify data across clinical and operational workflows and provide personalized AI-powered experiences.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-powered breast cancer detection
  • Supports radiologists in decision-making
  • Functions as independent reader
  • Functions as concurrent reader
  • Triage tool for breast screening
  • Enhanced workflow efficiency
  • Improved diagnostic accuracy
  • Seamless integration into existing workflows

Use Cases

  • Breast cancer screening programs
  • Radiologist support in mammography interpretation
  • Optimizing diagnostic workflows
  • Large-scale diagnostic and screening programs

What Physicians Need to Know

Evidence Base
MIA (Mammography Intelligent Assessment) is built upon a foundation of extensive deep learning research and clinical studies focused on mammography analysis. It leverages large datasets of mammograms to learn patterns associated with breast cancer.
Clinical Validation Studies
MIA has undergone rigorous clinical validation. Studies have demonstrated its ability to detect breast cancer with comparable or superior accuracy to human radiologists, particularly in identifying subtle cancers that might be missed. Key studies include those published in Nature Medicine and other peer-reviewed journals, showcasing its performance across diverse populations and mammography types.
Alert Fatigue Management
MIA is designed to be a supportive tool, not an overwhelming one. It highlights areas of concern on mammograms, allowing radiologists to focus their attention efficiently rather than generating numerous low-value alerts. The system aims to reduce the cognitive load by pre-screening and prioritizing.
Clinical Workflow Integration
MIA is designed for seamless integration into existing breast screening workflows. It can be incorporated into PACS (Picture Archiving and Communication Systems) to provide AI-powered insights directly within the radiologist's reading environment, minimizing disruption.
Decision Audit Trail
The system provides a clear audit trail of its analysis, indicating the regions of interest identified by the AI. This transparency allows radiologists to understand the basis of MIA's suggestions and supports their final diagnostic decisions.
Physician Tip

Utilize MIA as a 'second reader' to enhance confidence and potentially reduce recall rates. Pay close attention to areas flagged by MIA, especially in dense breast tissue. Integrate MIA's insights into your overall assessment, combining AI findings with patient history and other imaging modalities for a comprehensive diagnosis.

MIA is designed to integrate with standard PACS and reporting systems used in radiology departments, ensuring a smooth transition into existing clinical workflows without requiring significant changes to infrastructure.

Details

Category Clinical Decision Support & Reference, Population Health Analytics, Radiology & Imaging AI
Pricing Unknown unknown
DeploymentCloud-native (DeepHealth OS), AWS Marketplace, on-premise (interoperable with legacy PACS).
API AvailableUnknown
TrainingUnknown
Target SizeThousands of imaging centers and radiology departments around the world, large-scale diagnostic and screening programs.
Compliance
BAA Available Yes AI-estimated
HIPAA Compliant Yes AI-estimated
FDA Status 1 AI-estimated

DeepHealth has received FDA 510(k) clearance for its Prostate AI solution (part of Prostate Suite), Brain Health and Brain Age solutions (part of Neuro Suite), and TechLive™ remote scanning solution.

GDPRUnknown AI-estimated
Integrations
EHR Not specified
Specialties Oncology, Radiology, Women's Health

Social Proof

CustomersOver 2,890 customers worldwide.
Notable
RadNet (parent companydeploying across 400+ imaging centers)ONRAD (manages over 1.4 million exams annually and provides services to over 120 customer facilities in the U.S.).

Support & Reliability

Training ProvidedUnknown

What the Web Says

DeepHealth, formerly Kheiron Medical Technologies, develops AI-powered software to enhance the accuracy and efficiency of medical diagnostics, primarily focusing on breast cancer screening with its Miau00ae platform. The company has expanded its offerings to include solutions for prostate, chest, neuro, and thyroid health. DeepHealth aims to address the growing demand for radiology services and radiologist shortages by integrating AI into clinical workflows.

Overall: Positive

Strengths

  • Increased breast cancer detection rates (up to 12-13% more cancers detected).
  • Reduced radiologist workload (up to 30-44.8% in some scenarios).
  • Earlier detection of high-grade and invasive cancers, leading to better patient outcomes and survival rates.
  • Decreased unnecessary recalls for further assessment.
  • Reduced time to notify patients of results (from 14 days to 3 days).
  • Improved diagnostic consistency and accuracy across different mammography equipment vendors and radiologists.

Limitations

  • Concerns about AI's generalization across heterogeneous deployment environments and diverse population groups.
  • Potential for increased arbitration rates in AI-assisted workflows.
  • One review mentioned that the machine learning element of Mia was disabled due to UK health regulation, preventing it from learning on the job.
  • Some employee reviews (for RadNet/DeepHealth) mention issues with compensation/benefits, being overworked, and toxic micromanagement, though these are not specific to the Mia product.
  • Acquisition price of Kheiron Medical by RadNet/DeepHealth was surprisingly low ($1 million USD), suggesting potential financial struggles or challenges in commercialization despite strong technology.
  • The work wasn't quite what an intern was most interested or competent at - had done very little with Python or cloud computing before.

Based on reviews from: Handshake, Indeed.com, Healthcare Digital, DeepHealth (RadNet), Digital Health in Europe, YouTube (Kheiron Medical Technologies), ESR Connect, RadNet, Applied Radiology, Tracxn, MedicalExpo, Google Cloud (YouTube), Reddit, Pulse+IT News, Femtech Insider, MedTech Innovator, PMC (PubMed Central), Imperial News, Medium

Last updated: 2026-06-22

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate DeepHealth (formerly Kheiron Medical Technologies)

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

DeepHealth
DeepHealth Achieves Multiple Regulatory Milestones for Neuro, Prostate and LumbarMR
DeepHealth has received CE Marking for its Neuro Suite's Brain Health and Brain Age solutions, its LumbarMR solution, and both FDA 510(k) clearance and CE Marking for its Prostate AI solution. These regulatory clearances expand DeepHealth's portfolio of AI-powered clinical solutions for radiology.
2026-05
Imaging Technology News
DeepHealth Advances with Key Regulatory Approvals for AI Imaging Solutions
DeepHealth has secured significant regulatory approvals for its AI-driven imaging technologies, including CE Marking for its Brain Health and Brain Age tools (Neuro Suite) and LumbarMR solution, and both FDA 510(k) clearance and CE Marking for its Prostate AI solution. These approvals strengthen DeepHealth's position in the radiology sector.
2026-05
DeepHealth
DeepHealth Expands Breast Suite with New FDA-Cleared AI Capabilities
DeepHealth has received FDA 510(k) clearances for Breast Arterial Calcification Assessment and the integration of prior exams into its ProFound Pro AI-powered cancer detection application, introducing Mammo Dx1. This expands the capabilities of their Breast Suite.
2026-05
DeepHealth
DeepHealth momentum contributes to RadNet's record Q1 2026 financial results
DeepHealth, as RadNet's Digital Health division, has shown continued growth in revenue, customer momentum, and expansion of its AI-powered health informatics portfolio, contributing to RadNet's record first-quarter 2026 financial results.
2026-04
DeepHealth
GE HealthCare expands mammography collaboration with RadNet's DeepHealth subsidiary to extend global access to DeepHealth's AI
GE HealthCare has expanded its collaboration with DeepHealth to further innovation, commercialization, and adoption of advanced AI-powered mammography tools, aiming to extend global access to DeepHealth's AI-powered breast cancer screening solutions.
2026-04
RadNet Inc.
DeepHealth Launches Reporting Pro, Bringing AI Automation to Radiology Reporting
DeepHealth has launched Reporting Pro, a new AI-powered solution designed to automate and transform how radiologists generate clinical reports. This solution integrates speech recognition, clinical AI findings, measurements, AI-generated impressions, and quality assurance.
2026-06
RadNet
DeepHealth Unveils Industry's Most Comprehensive Portfolio of Native Clinical AI Solutions at ECR 2026
DeepHealth unveiled its expanded portfolio of native clinical AI solutions and services across all core imaging modalities at ECR 2026, aiming to deliver the next era of AI-powered health informatics. This includes solutions for breast, prostate, chest, neuro, and thyroid health.
2026-03
DeepHealth
Landmark Nature Health Study Demonstrates the Effectiveness of DeepHealth's Novel AI-Powered Breast Cancer Detection Workflow
A study published in Nature Health demonstrated the clinical effectiveness of DeepHealth's AI technology in an AI-powered breast cancer detection workflow, showing a 21.6% increase in cancer detection rate. The study included over 579,000 women across 109 imaging sites in the US.
2025-11

Videos

Product demos, reviews, and walkthroughs for DeepHealth (formerly Kheiron Medical Technologies).

Loading videos...

View all on YouTube

Frequently Asked Questions

DeepHealth's AI, Mia, is designed to integrate seamlessly with standard PACS systems, providing a 'second read' to support radiologists. It analyzes mammograms and highlights areas of suspicion, aiming to reduce reading times and improve accuracy without disrupting your current workflow.
Yes, DeepHealth's Mia is FDA cleared for use as an AI-enabled medical device for breast cancer screening. It also holds CE Mark certification, demonstrating compliance with European regulatory standards for medical devices.
Clinical studies have shown that DeepHealth's Mia can help detect cancers earlier and reduce the number of false positives, leading to improved patient outcomes and reduced recall rates. It acts as an independent reader, providing a consistent and objective assessment of mammograms.
While DeepHealth's AI is trained on diverse datasets, like all AI, it may have limitations in specific, underrepresented populations or extremely dense breast tissue. Continuous monitoring and updates are performed to address potential biases and improve performance across all patient demographics.
DeepHealth typically offers subscription-based pricing models, which can vary depending on the volume of studies and integration requirements. It's best to contact their sales team directly for a customized quote that aligns with your practice's specific needs and budget.
Several other AI solutions exist for breast cancer screening. DeepHealth differentiates itself through its extensive clinical validation, seamless integration capabilities, and a focus on providing a truly independent 'second read' to augment, rather than replace, radiologist expertise.
DeepHealth provides comprehensive training and ongoing support for physicians and their staff, including onboarding, technical assistance, and educational resources. This ensures smooth integration and optimal utilization of the AI solution within your clinical practice.

Related Tools

OCTA
OCTA
Clinical Decision Support & Reference
OCTA Flow is an AI-powered platform that assists ophthalmologists in analyzing Optical Coherence Tomography Angiography (OCTA) scans to enhance diagnostic accuracy and efficiency.
Elsevier
Elsevier
Clinical Decision Support & Reference
ClinicalKey AI is a clinical decision support tool that uses artificial intelligence to provide physicians with rapid access to evidence-based medical information.
EvidenceMD
EvidenceMD
Clinical Decision Support & Reference
EvidenceMD is an AI-powered clinical decision support platform that provides physicians with rapid access to current and relevant medical evidence for informed decision-making.
FAITH project
AI Agent
Clinical Decision Support & Reference
The FAITH project focuses on Federated Artificial Intelligence for Trusted Healthcare, aiming to develop secure and privacy-preserving AI solutions for healthcare, including potential applications for physician directories.
AI-based support system for skin cancer diagnostics
German Cancer Research Center (DKFZ)
Clinical Decision Support & Reference
Scientists at the German Cancer Research Center have developed an AI-based support system for skin cancer diagnostics that explains its decisions, increasing doctors' confidence in both the AI and their own diagnoses.
Prof. Valmed
Prof. Valmed - validated medical information GmbH
Clinical Decision Support & Reference
Prof. Valmed is Europe's first CE Class IIb certified AI-supported medical co-pilot, providing healthcare professionals with validated, evidence-based medical information through an innovative AI platform.

See all Clinical Decision Support & Reference tools →

Suggest an Edit → | Last Verified: 2026-07-03 | First Added: 2026-06-21
AI Tool Finder
AI-powered search. Results may not be comprehensive.